Published by Wanda Rich
Posted on September 20, 2021
Plasma Fractionation Marketis valued atUSD 20.70 Billionin 2018 and expected to reachUSD 33.24 Billionby 2025 with theCAGR of 7.25%over the forecast period.
Plasma Fractionation Market:Global Size, Trends, Competitive, Historical & Forecast Analysis, 2021-2027.Rising prevalence of respiratory diseases like alpha-1 antitrypsin deficiency (ATTD) along with growing geriatric population and increasing use of immunoglobulins in various therapeutic applications are some of the key factors accelerating the plasma fractionation market globally.
Get Sample Report:@https://brandessenceresearch.com/requestSample/PostId/1298
Blood fractionation is the process of fractionating whole blood, or separating it into its component parts. This is naturally done by centrifuging the blood. Fractionation is a process which is carried out to separate certain quantity of mixture. Plasma-derived immunoglobulins are giving a new narrative to healthcare across a wide range of autoimmune and inflammatory diseases. Plasma contains a large variety of proteins including albumin, immunoglobulins, and clotting proteins such as fibrinogen. It is also employed to stop excessive blood loss during surgical procedures. Similarly, immunoglobulins are employed in the treatment of primary and secondary immune deficiencies. Plasma imitative immunoglobulins are being progressively used in multiple clinical indications such as autoimmune and inflammatory diseases.
Plasma Fractionation market report is segmented on the basis of product type, application, end user and by regional & country level. Based upon product type, plasma fractionation market is classified into immunoglobulin, coagulation factor, concentrates, albumin, protease inhibitors and others. Based upon application, plasma fractionation market is classified into neurology, immunology, homology, critical care, pulmonology, hemoto-oncology, rheumatology and others. Based upon end user, plasma fractionation market is classified into hospitals & clinics, clinical research laboratories and academic institutes.
The regions covered in this Plasma Fractionation market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of Plasma Fractionation is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.
Plasma fractionation market report covers prominent players are,
FDA Approved Grifols New GamaSTAN (immune globulin [human]) to Treat Patients Exposed to Hepatitis A and Measles
News: SEPTEMBER 4, 2018, GamaSTAN is the only protected globulin product on the U.S. market accepted for immediate protection against HAV and measles. Grifols a leading worldwide producer of plasma-derived medicines, announced that the U.S. Food and Drug Administration (FDA) has approved a new formulation of its GamaSTAN immune globulin (human) for hepatitis A virus (HAV) and measles postexposure prophylaxis. GamaSTAN is now available to healthcare providers across the country.
The global plasma fractionation market is witnessing substantial growth due to rising prevalence of respiratory diseases like alpha-1 antitrypsin deficiency (ATTD) along with growing geriatric population and increasing use of immunoglobulins in various therapeutic applications are some of the factors driving the growth of the plasma fractionation across the globe. According to the European Respiratory Journal, 2017, it is estimated that the number of diagnosed AATD patients in Germany was 19162, of whom an estimated 8684 patients would have had an additional pulmonary diagnosis. In addition, according to the WHO, Respiratory diseases are leading causes of death and disability in the world. About 65 million persons suffer from chronic obstructive pulmonary disease (COPD) and 3 million die from it each year, making it the third leading cause of death worldwide. About 334 million people suffer from asthma, the most common chronic disease of childhood affecting 14% of all children globally. However, the high cost of plasma products, limited reimbursements, and the emergence of recombinant alternatives are expected to restrain the growth of this market during the forecast period. Furthermore, various advancements in the product by major manufacturers and increasing technological innovation for plasma proteins are major opportunities for the plasma fractionation market.
North America is dominating the plasma fractionation market with the potential rate due to increasing use of immunoglobulin in various therapeutic areas, growing geriatric population, and the increasing prevalence of respiratory diseases. According to the U.S. Census Bureau, Population Projections, the number of Americans ages 65 and older isprojected to nearly doublefrom 52 million in 2018 to 95 million by 2060, and the 65-and-older age group’s share of the total population will rise from 16 percent to 23 percent. And additionally, in 2018, 24 percent of men and about 16 percent of women ages 65 and older remained in the labor force. These levels are predictable to rise additional by 2026, to 26 percent for men and 18 percent for women.
The Asia Pacific is expected to emerge as the fastest-growing regional market over the forecast period due to increase in plasma collection (and the number of plasma collection centers), and the increasing use of alpha-1-antitrypsin are drive the market in this region. According to the WHO report, an increase of 7.8 million blood donations from voluntary unpaid donors has been reported from 2013 to 2018.Only 55 of 171 reporting nations create plasma-derived medicinal products (PDMP) through the fractionation of plasma together in the reporting country.
By Product Type:Immunoglobulin, Coagulation Factor Concentrates, Albumin, Protease Inhibitors, Others
By Application:Neurology, Immunology, Homology, Critical Care, Pulmonology, Hemoto-Oncology, Rheumatology, Others
By End user:Hospitals & Clinics, Clinical Research Laboratories, Academic Institutes
Regional & Country Analysis
North America, U.S., Mexico, Canada , Europe, UK, France, Germany, Italy , Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of Middle East and Africa
This comprehensive report will provide:
Our Market Research Solution Provides You Answer to Below Mentioned Question:
Get Full Report: @https://brandessenceresearch.com/heavy-industry/plasma-fractionation-market-industry-analysis
About us: Brandessence Market Research and Consulting Pvt. Ltd.
Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals, and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations, and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.
Contact us at: +44-2038074155 or mail us atsales@brandessenceresearch.com
Plasma Fractionation Marketis valued atUSD 20.70 Billionin 2018 and expected to reachUSD 33.24 Billionby 2025 with theCAGR of 7.25%over the forecast period.
Plasma Fractionation Market:Global Size, Trends, Competitive, Historical & Forecast Analysis, 2021-2027.Rising prevalence of respiratory diseases like alpha-1 antitrypsin deficiency (ATTD) along with growing geriatric population and increasing use of immunoglobulins in various therapeutic applications are some of the key factors accelerating the plasma fractionation market globally.
Get Sample Report:@https://brandessenceresearch.com/requestSample/PostId/1298
Blood fractionation is the process of fractionating whole blood, or separating it into its component parts. This is naturally done by centrifuging the blood. Fractionation is a process which is carried out to separate certain quantity of mixture. Plasma-derived immunoglobulins are giving a new narrative to healthcare across a wide range of autoimmune and inflammatory diseases. Plasma contains a large variety of proteins including albumin, immunoglobulins, and clotting proteins such as fibrinogen. It is also employed to stop excessive blood loss during surgical procedures. Similarly, immunoglobulins are employed in the treatment of primary and secondary immune deficiencies. Plasma imitative immunoglobulins are being progressively used in multiple clinical indications such as autoimmune and inflammatory diseases.
Plasma Fractionation market report is segmented on the basis of product type, application, end user and by regional & country level. Based upon product type, plasma fractionation market is classified into immunoglobulin, coagulation factor, concentrates, albumin, protease inhibitors and others. Based upon application, plasma fractionation market is classified into neurology, immunology, homology, critical care, pulmonology, hemoto-oncology, rheumatology and others. Based upon end user, plasma fractionation market is classified into hospitals & clinics, clinical research laboratories and academic institutes.
The regions covered in this Plasma Fractionation market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of Plasma Fractionation is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.
Plasma fractionation market report covers prominent players are,
FDA Approved Grifols New GamaSTAN (immune globulin [human]) to Treat Patients Exposed to Hepatitis A and Measles
News: SEPTEMBER 4, 2018, GamaSTAN is the only protected globulin product on the U.S. market accepted for immediate protection against HAV and measles. Grifols a leading worldwide producer of plasma-derived medicines, announced that the U.S. Food and Drug Administration (FDA) has approved a new formulation of its GamaSTAN immune globulin (human) for hepatitis A virus (HAV) and measles postexposure prophylaxis. GamaSTAN is now available to healthcare providers across the country.
The global plasma fractionation market is witnessing substantial growth due to rising prevalence of respiratory diseases like alpha-1 antitrypsin deficiency (ATTD) along with growing geriatric population and increasing use of immunoglobulins in various therapeutic applications are some of the factors driving the growth of the plasma fractionation across the globe. According to the European Respiratory Journal, 2017, it is estimated that the number of diagnosed AATD patients in Germany was 19162, of whom an estimated 8684 patients would have had an additional pulmonary diagnosis. In addition, according to the WHO, Respiratory diseases are leading causes of death and disability in the world. About 65 million persons suffer from chronic obstructive pulmonary disease (COPD) and 3 million die from it each year, making it the third leading cause of death worldwide. About 334 million people suffer from asthma, the most common chronic disease of childhood affecting 14% of all children globally. However, the high cost of plasma products, limited reimbursements, and the emergence of recombinant alternatives are expected to restrain the growth of this market during the forecast period. Furthermore, various advancements in the product by major manufacturers and increasing technological innovation for plasma proteins are major opportunities for the plasma fractionation market.
North America is dominating the plasma fractionation market with the potential rate due to increasing use of immunoglobulin in various therapeutic areas, growing geriatric population, and the increasing prevalence of respiratory diseases. According to the U.S. Census Bureau, Population Projections, the number of Americans ages 65 and older isprojected to nearly doublefrom 52 million in 2018 to 95 million by 2060, and the 65-and-older age group’s share of the total population will rise from 16 percent to 23 percent. And additionally, in 2018, 24 percent of men and about 16 percent of women ages 65 and older remained in the labor force. These levels are predictable to rise additional by 2026, to 26 percent for men and 18 percent for women.
The Asia Pacific is expected to emerge as the fastest-growing regional market over the forecast period due to increase in plasma collection (and the number of plasma collection centers), and the increasing use of alpha-1-antitrypsin are drive the market in this region. According to the WHO report, an increase of 7.8 million blood donations from voluntary unpaid donors has been reported from 2013 to 2018.Only 55 of 171 reporting nations create plasma-derived medicinal products (PDMP) through the fractionation of plasma together in the reporting country.
By Product Type:Immunoglobulin, Coagulation Factor Concentrates, Albumin, Protease Inhibitors, Others
By Application:Neurology, Immunology, Homology, Critical Care, Pulmonology, Hemoto-Oncology, Rheumatology, Others
By End user:Hospitals & Clinics, Clinical Research Laboratories, Academic Institutes
Regional & Country Analysis
North America, U.S., Mexico, Canada , Europe, UK, France, Germany, Italy , Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of Middle East and Africa
This comprehensive report will provide:
Our Market Research Solution Provides You Answer to Below Mentioned Question:
Get Full Report: @https://brandessenceresearch.com/heavy-industry/plasma-fractionation-market-industry-analysis
About us: Brandessence Market Research and Consulting Pvt. Ltd.
Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals, and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations, and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.
Contact us at: +44-2038074155 or mail us atsales@brandessenceresearch.com
Explore more articles in the Research Reports category
